Trial · NCT03523728
Participant flow45
How many started, completed or left each group, period by period.
21 to 40 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Stage 2 (24 Months) | Treated | Stage 1- Placebo | 0 | |
| Stage 2 (24 Months) | Treated | Stage 1- Venglustat 8 mg | 0 | |
| Stage 2 (24 Months) | Treated | Stage 1- Venglustat 15 mg | 0 | |
| Stage 2 (24 Months) | Treated | Stage 2- Placebo | 122 | |
| Stage 2 (24 Months) | Treated | Stage 2- Venglustat 15 mg | 119 | |
| Stage 2 (24 Months) | Estimated Glomerular Filtration Rate (eGFR) Between 45 and 89.9 mL/Min/1.73 m^2 at Screening | Stage 1- Placebo | 0 | |
| Stage 2 (24 Months) | Estimated Glomerular Filtration Rate (eGFR) Between 45 and 89.9 mL/Min/1.73 m^2 at Screening | Stage 1- Venglustat 8 mg | 0 | |
| Stage 2 (24 Months) | Estimated Glomerular Filtration Rate (eGFR) Between 45 and 89.9 mL/Min/1.73 m^2 at Screening | Stage 1- Venglustat 15 mg | 0 | |
| Stage 2 (24 Months) | Estimated Glomerular Filtration Rate (eGFR) Between 45 and 89.9 mL/Min/1.73 m^2 at Screening | Stage 2- Placebo | 97 | |
| Stage 2 (24 Months) | Estimated Glomerular Filtration Rate (eGFR) Between 45 and 89.9 mL/Min/1.73 m^2 at Screening | Stage 2- Venglustat 15 mg | 90 | |
| Stage 2 (24 Months) | eGFR Between 30 and 44.9 mL/Min/1.73 m^2 at Screening | Stage 1- Placebo | 0 | |
| Stage 2 (24 Months) | eGFR Between 30 and 44.9 mL/Min/1.73 m^2 at Screening | Stage 1- Venglustat 8 mg | 0 | |
| Stage 2 (24 Months) | eGFR Between 30 and 44.9 mL/Min/1.73 m^2 at Screening | Stage 1- Venglustat 15 mg | 0 | |
| Stage 2 (24 Months) | eGFR Between 30 and 44.9 mL/Min/1.73 m^2 at Screening | Stage 2- Placebo | 25 | |
| Stage 2 (24 Months) | eGFR Between 30 and 44.9 mL/Min/1.73 m^2 at Screening | Stage 2- Venglustat 15 mg | 29 | |
| Stage 2 (24 Months) | COMPLETED | Stage 1- Placebo | 0 | |
| Stage 2 (24 Months) | COMPLETED | Stage 1- Venglustat 8 mg | 0 | |
| Stage 2 (24 Months) | COMPLETED | Stage 1- Venglustat 15 mg | 0 | |
| Stage 2 (24 Months) | COMPLETED | Stage 2- Placebo | 0 | |
| Stage 2 (24 Months) | COMPLETED | Stage 2- Venglustat 15 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03523728/flow?page=2